JWH-193 is a drug from the aminoalkylindole and naphthoylindole families which acts as a cannabinoidreceptoragonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a binding affinity at the CB1 receptor of 6 nM, binding around seven times more tightly than the parent compound JWH-200,[1] though with closer to twice the potency of JWH-200 in activity tests.
A structural isomer of JWH-193 with the methyl group on the indole ring instead of the naphthoyl ring, was also found to be of similarly increased potency over JWH-200.[3][4]
^Huffman JW, Padgett LW (2005). "Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes". Current Medicinal Chemistry. 12 (12): 1395–411. doi:10.2174/0929867054020864. PMID15974991.